Reordering Mounjaro: when to do it and how the process works

Step 1: Know when your pen runs out (earlier than you think)

A single Mounjaro pen holds four doses. If you inject on the same day each week, your pen is finished after exactly 28 days. The practical lesson: don't wait until the last dose before you reorder.

Most people find that placing a repeat order around day 21 (after their third injection from the current pen) gives enough lead time. A prescriber still needs to review your case, and even a fast turnaround takes a working day. If a clinical question comes up, a little extra time means you're not injecting on a countdown. Our guide on exactly when to reorder Mounjaro covers this in more detail, including how titration timing affects the window.

One practical detail worth knowing: your pen lives in the fridge between uses, so it's easy to forget you're drawing from the same cartridge every week. A quick note stuck to the fridge door with your injection day and dose number can save that mild panic when you suddenly realise you're on your last dose.

Step 2: Submit your repeat request and clinical review

At nume, every repeat order begins with a short clinical check-in. A GPhC-registered Independent Prescriber reads your responses, not a software algorithm, not an automated flag system. They look at how treatment has been going: any side effects you've noticed, whether your weight progress is on track, and whether a dose increase is due under your titration plan.

This is consistent with how Mounjaro is meant to be used. The NHS patient information for tirzepatide, available on the NHS website, sets out that dosing decisions are made by your prescriber throughout treatment, they are not fixed at the start and left alone. If you're due to move up from your current dose, that conversation happens here, at the repeat stage. Evidence of your current dose may be requested for transfers or increases, in line with safe-prescribing practice.

Order by noon Monday to Friday and, once clinically approved, your pen is dispatched the same day and delivered free the next working day by DPD, in plain unbranded packaging. There is no subscription and no auto-renewal, each repeat is a distinct clinical decision.

Step 3: What the prescriber actually checks

The repeat review is brief from your side but substantive from theirs. The prescriber considers whether you've tolerated your current dose well, whether any new symptoms or medicines need flagging, and whether your weight trajectory suggests treatment is working as expected. NICE's appraisal of tirzepatide, TA1026, notes that continuing treatment should be reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose, so progress genuinely feeds into clinical decisions, not just at the start of treatment but throughout.

This is also the moment to raise anything you've been wondering about: an unusual side effect, a question about your injection technique, or whether the pen storage accessories you're using are appropriate. The aftercare team at nume is available seven days a week if something comes up between orders.

For context on how the broader cost and pricing landscape affects repeat prescriptions, the Eli Lilly UK price increase explained covers what changed in September 2025 and why private prices vary by provider.

Step 4: What happens if there's a clinical query or a dose change

Occasionally a prescriber will want more information before approving a repeat, perhaps because a side effect you've mentioned warrants a follow-up question, or because a dose increase requires supporting evidence. This isn't a rejection; it's the system working as it should. Respond as promptly as you can and the review moves forward quickly.

If you're being titrated up (say, from 5mg to 7.5mg) your new pen will reflect the updated dose. The tirzepatide overview explains the full UK dose schedule from 2.5mg to 15mg, and why the incremental approach matters for tolerability, and if you're curious about the highest strength in particular, our page on 50mg tirzepatide goes into further detail on that end of the range. The same page covers how the dual GIP and GLP-1 mechanism behind Mounjaro differs from single-agonist medicines, which is useful background for anyone exploring their treatment options more broadly.

If you have questions about your repeat that aren't answered in your confirmation or the patient information leaflet, the contact page reaches the support team directly, and the FAQs cover the most common repeat-order queries. For anyone thinking about starting treatment rather than reordering, the Mounjaro overview is the right starting point.